NCT03227263View on ClinicalTrials.gov

BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

May 15, 2020

Study Completion Date

May 15, 2020

Conditions
Rendu Osler DiseaseTelangiectasia, Hereditary Hemorrhagic
Interventions
DRUG

Bevacizumab

Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations

DRUG

sodium chloride 0.9%

0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations

Trial Locations (4)

Unknown

CHU d'Angers, Angers

Hôpital Ambroise Paré, Boulogne-Billancourt

Hôpital Femme Mère Enfant, Bron

CHU de Montpellier Hôpital St Eloi, Montpellier

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03227263 - BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). | Biotech Hunter | Biotech Hunter